30 closest matches · ranked by relevance
Chalazion Unspecified Eye, Unspecified Eyelid · Chalazion Left Eye, Unspecified Eyelid · Chalazion Right Eye, Unspecified Eyelid
Primary: Number of Participants With Complete Resolution — 13; 12; 11 participants
Chalazion
Primary: The Proportions of Participants Who Experienced Complete Response of the Study Chalazion by Day 15 ± 1 — 28; 32 Participants — p=0.579
Chalazion · Dry Eye Syndromes
Primary: Meibomian Gland Assessment (Total Meibomian Gland Secretion Score) — 6.3; 5.6; 14.3; 6.1 Scores on a scale
Chalazion
Primary: Time Taken for a Complete Resolution of the Chalaziosis — 51.2; 28.4 days
Chalazion · Dry Eye Syndromes
Primary: Association Between Screening Methods (Meibomian Gland Expression) and Treatment Effectiveness Outcomes (Total Meibomian Gland Score) — 0.4816 Correlation coefficient…
Dry Eye
Primary: Non-invasive Tear Break up Time (TBUT) — 3.9; 4.0 seconds
Chalazion · Hordeolum
Primary: Treatment Emergent Adverse Events — 2; 0; 1; 1 participants
Dry Eye Syndromes · Dry Eye · Meibomian Gland Dysfunction
Primary: Score and Change From Baseline in Tear Break Up Times (TBUT), as Assessed by a Masked Rater — 4.0; 1.9; 3.4; 4.7 seconds
Blepharoptosis · Ptosis, Eyelid · Myasthenia Gravis
Primary: Interpalpebral Fissure (IPF) During Spontaneous Blink — 2.4; 4.1; 1.1 millimeters — p=<0.001
Meibomian Gland Dysfunction · Dry Eye Syndromes · Dry Eye
Primary: Changes in Tear Break Up Times (TBUT) to the 4-weeks Follow-up Exam — 4.3; 4.6; 3.0; 2.7 seconds
Meibomian Gland Dysfunction · Posterior Blepharitis
Primary: Ocular Surface Disease Index — 56.6; 46.4; 48.4 units on a scale
Trachoma
Primary: Number of Eyelids With Presence of Recurrent Trichiasis — 948; 1062; 721; 612 eyelids
Meibomian Gland Dysfunction · Dry Eye
Primary: Dry Eye Questionnaire 5 (DEQ-5) Score — 11.8; 11.8 score on a scale — p=0.02
Eyelid Sebaceous Gland Carcinoma
Primary: Sentinel Lymph Node Positivity — 2 Participants
Posterior Blepharitis
Primary: Change of Blepharitis Symptoms Score — 1.8; 2.8 score — p=0.03
Acquired Blepharoptosis
Primary: Percentage of Subjects With Treatment-Emergent Adverse Events [Safety and Tolerability]) — 0; 0; 0 Participants
Antibiotic Side Effect · Eyelid; Wound · Eyelid Diseases
Primary: Number of Participants With Surgical Site Infections — 0; 5 Participants — p=0.025
Lower Eyelid Steatoblepharon (Excess Eyelid Fat)
Primary: Lower Eyelid Steatoblepharon Severity (LESS) Score--Clinician-Reported — 27; 6 participants — p=0.020
Meibomian Gland Dysfunction (MGD) · Contact Lens Discomfort (CLD)
Primary: Primary Efficacy for MGD: Change From Baseline to Month 4 in Meibum Gland Secretion Score (MGS). — 12.1; 16 Units on the Meibomian Gland Score scale
Meibomian Gland Dysfunction · Dry Eye
Primary: Stage 1 Mean Change in Total Meibomian Gland Score From Baseline to 3 Months — 11.6; 4.5 units on a scale — p=<0.0001
Uveitis · Uveitis, Posterior · Uveitis, Anterior
Primary: Adverse Events — 27; 1 Participants
Meibomian Gland Dysfunction
Primary: Meibum Gland Secretion Score (MGS) — 0.5; 7.4 score on a scale
Blepharitis · Dry Eye Syndrome
Primary: Mean Change in Total Meibomian Gland Score — 12.8; 1.9 Change in Meibomian Gland Score
Blepharitis
Primary: Visual Analogue Scale (VAS - Ranges 0-100 mm) — 36.5; 28.5 units on a scale (from 0 to 100 mm) — p=0.072
Meibomian Gland Dysfunction
Primary: IOP Related to Safety — 15.906; 16.452; 16.469 mmHg
Chlamydial Conjunctivitis
Primary: Total Number of Participants With Negative Chlamydia Direct Fluorescent Antibody (DFA) Test Results After Oral Azithromycin Treatments — 27 participants
Blepharitis
Primary: Change From Baseline in Ocular Discomfort — -4.1; -2.4 score on a scale
Cataracts · Meibomian Gland Dysfunction (MGD)
Primary: Mean Monocular UCDVA (Uncorrected Distance Visual Acuity) — 0.08; 0.07 LogMAR
Presbyopia
Primary: Change in Binocular Distance-corrected Near Visual Acuity (DCNVA) From Baseline — 6.1; 4.5 number of letters read correctly — p=0.1832
Posterior Blepharitis · Meibomian Gland Dysfunction
Primary: Adverse Events — 1; 1; 2; 0 adverse events